HLA binding peptides and their uses

Details HLA binding peptides and their uses HLA binding peptides and their uses

2007-08-07

2007-08-07

Schwadron, Ronald B. (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Cancer cell or component thereof

C424S185100, C424S450000, C514S002600, C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000

Reexamination Certificate

active

09189702

ABSTRACT:
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus,mycobacterium tuberculosis(MT), p53, CEA, trypanosome surface antigen (TSA) and Her2
eu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.

REFERENCES:
patent: 4599230 (1986-07-01), Milich et al.
patent: 5028425 (1991-07-01), Good et al.
patent: 5200320 (1993-04-01), Sette et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5462871 (1995-10-01), Boon-Falleur et al.
patent: 5503829 (1996-04-01), Ladant et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5686068 (1997-11-01), Melief et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 5750395 (1998-05-01), Fikes et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5840303 (1998-11-01), Chisari et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6063900 (2000-05-01), Melief et al.
patent: 6075122 (2000-06-01), Cheever et al.
patent: 6514942 (2003-02-01), Ioannides et al.
patent: 44710 (1982-01-01), None
patent: 0226513 (1987-06-01), None
patent: 0346022 (1989-06-01), None
patent: 0534615 (1996-08-01), None
patent: 0728764 (1996-08-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO92/12996 (1992-08-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 93/03753 (1993-03-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 93/17095 (1993-09-01), None
patent: WO 93/20103 (1993-10-01), None
patent: WO 93/22338 (1993-11-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO94/05304 (1994-03-01), None
patent: WO 94/11738 (1994-05-01), None
patent: 94/20127 (1994-09-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/11255 (1995-04-01), None
patent: WO 95/23234 (1995-08-01), None
patent: 96/18409 (1996-06-01), None
patent: WO96/18409 (1996-06-01), None
patent: 96/22067 (1996-07-01), None
patent: WO 97/04802 (1997-02-01), None
patent: WO 97/29195 (1997-08-01), None
patent: WO 97/41440 (1997-11-01), None
patent: WO 98/33888 (1998-08-01), None
patent: WO 01/41788 (2001-06-01), None
Tsang et al., J. Nat Cancer Inst., 87:892-990, 1995.
J. Blok and G.M. Air,Virology(1982) 121: 211-229.
Houbiers et al.,Eur. J. Immunol.(1993) 23: 2072-2077.
Gnjatic et al.,Eur. J. Immunol.(1995) 25: 1638-1642.
Konda et al., “Prominent Roles in Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules,”Journal of Immunology(1995) 155: 4307-4312.
Nijman, H.W. et al. (1993)Journal of Immunotherapy14(2):121-126.
Ras, E. et al. (1997)Human Immunology53:81-89.
Zaremba, S. et a. (1997)Cancer Research57:4570-4577.
Gnjatic, S., et al., “Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules,”Eur. J. Immunol. 25:1638-1642, VCH Verlagsgesellschaft mbH (1995).
Harlow, E. et al., “Molecular Cloning and In Vitro Expression of a cDNA Clone for Human Cellular Tumor Antigen p53,”Mol. Cell. Biol. 5: 1601-1610, American Society for Microbiology (1985).
Harris, N., et al., “Molecular Basis for Heterogeneity of the Human p53 Protein,”Mol. Cell. Biol. 6:4650-4656, American Society for Microbiology (1986).
Lamb, P., and Crawford, L., “Characterization of the Human p53 Gene,”Mol. Cell. Biol. 6:1379-1385, American Society for Microbiology (1986).
Röpke, M., et al., “T Cell-Mediated Cytotoxicity Against p53-Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors,”Scand. J. Immunol. 42:98-103, Blackwell Science Limited (1995).
Toes, R.E.M., et al., “Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells,”J. Immunol. 160:4449-4456, The American Association of Immunologists (1998).
Vojtesek, B., et al., “Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein,”Oncogene 10:389-393, Stockton Press (1995).
Zakut-Houri, R., et al., “Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells,”EMBO J4:1251-1255, IRL Press Limited (1985).
Alexander et al. “Generation of Tumor-specific Cytolytic T Lymphocytes from Peripheral Blood of Cervical Cancer Patients by In Vitro Stimulation with a Synthetic Human Papillomavirus Type 16 E7 Epitope” Am. J. Obstet. Gynecol. 175:1586-1593 (1996).
Alexander et al., J. Immunol. (1997) 159:4753-4761.
Altfeld et al., J. Virol. (2001) 75:1301-1311.
Benjamin et al., Nature (1991) 351:74-77.
Bergmann et al., J. Virol. (1994) 68:5306-5310.
Bertoni et al., J. Clin. Invest. (1997) 100:503-513.
Bjorkman et al. “Structure of the Human Class I Histocompatibility Antigen HLA-A2” Nature 329:506 (1987).
Boel et al., Immunity (1995) 2:167.
Boon. Tumor Antigens Recognized by Cytoloytic T Lymohocytes: Present Perspectives for Specific Immunotherapy Int. J. Cancer 54:177-180 (1993).
Bosisio et al., Gazz. Chim. Ital. (1967) 97(12):1848-1857.
Bruss. “A Short Linear Sequence in the Pre-S Domain of the Large Hepatitis B Virus Envelope Protein Required from Virion Formation” J. Virology 71(12):9350-9357 (1997).
Buus et al. “Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia” Science 242:1045-1047 (1988).
Carreno et al. “HLA-B37 and HLA-A2.1 Molecules Bind Largely Nonoverlapping Sets of Peptides” Proc. Natl. Acad. Sci. USA 87:3420-3424 (1990).
Castellanos et al., Gynecologic Oncology (2001) 82:77-83.
Castellanos et al., Oncology/Hematology (2001) 39:133-138.
Celis et al. “Identification of Potential CTL Epitopes of Tumor Associated Antigen MAGE-1 for Five Common HLA-A Alleles” Molec. Immunol. 3:1423-1430 (1994).
Celis et al. “Epitope Selection and Develeopment of Peptide Based Vaccines to Treat Cancer” Cancer Biology 6:329-336 (1995).
Chang et al., J. Immunol. (1999) 162:1156-1164.
Chen and Parham, Nature (1989) 337:743-745.
Cotran et al. (ed.)Robbins Pathologic Basis of Disease, 4thed., W.B. Saunders Co., Philadelphia pp. 296-299 (1989).
Culmann et al., (1991) 146(5):1560-1565.
De Bruijn et al. “Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses” Eur. J. Immunol. 21:2963-2970 (1990).
Del Val et al., Cell (1991) 66:1145-1153.
DiBrino et al. “Endogenous Peptides Bound to HLA-A3 Possess a Specific Combination of Anchor Residues That Permit Identification of Potential Antigenic Peptides” Proc. Nat'l. Acad. Sci. USA 90:1508-1512 (1993).
Dibrino et al., J. Immunol. (1993) 151:5930-5935.
Diepolder et al., J. Virol. (1997) 71(8):6011-6019.
Ding et al. “Cloning and Analysis of MAGE-1-Related Genes” Biochem. Biophys. Res. Commun. 202(1):549-555 (1994).
Ding et al., Immunity (1998) 8:403-411.
Doolan et al., Immunity (1997) 7:97-112.
Doolan et al., J. Immunol. (2000) 165:1123-1137.
Edgington. “How Sweet It Is: Selection-Mediating Drugs” Biotechnology 10:383-389 (1992).
Eisenlohr et al., J. Exp. Med. (1992) 175:4

Affiliated with

Also associated with

Rating

HLA binding peptides and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HLA binding peptides and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA binding peptides and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3843330